Clinical Trial Update: Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial of inhaled triiodothyronine (T3) for COVID-19–associated ARDS has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome
• Respiratory Syndrome

Drugs mentioned

• Inhaled triiodothyronine (T3) (triiodothyronine)

Snippet

Sponsor: University of Minnesota | Conditions: Covid19, SARS-CoV Infection | Phase 2 | Status: WITHDRAWN